To investigate the clinical potential of BRD9 targeting through degradation or inhibition for ALL, we tested BRD9 degraders and the BRD9 inhibitor, EA-89, against primary ALL cells (patient details are provided in Supplementary Table 1). The gene discussed is BRD9; the disease is acute lymphoblastic leukemia.